NCT01035437

Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer

A Pilot Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Roswell Park Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aim is to find out what effects capecitabine, oxaliplatin and radiation therapy following photodynamic therapy have on esophageal cancer.

Conditions

• Esophageal Neoplasm

Interventions

Type	Name	Description
DRUG	HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)	HPPH in D5W, 4.0 mg/m2 infused over 1 hour

Timeline

• Start date: 2009-12-01
• Primary completion: 2011-01-01
• Completion: 2011-02-01
• First posted: 2009-12-18
• Last updated: 2012-07-02